search
Back to results

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Primary Purpose

Critical Limb Ischemia, Buerger's Disease

Status
Not yet recruiting
Phase
Phase 4
Locations
Malaysia
Study Type
Interventional
Intervention
Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
Sponsored by
Cell Biopeutics Resources Sdn Bhd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Limb Ischemia focused on measuring critical limb ischemia, Buerger's disease, bone marrow derived mesenchymal stem cell

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 years. Buerger's disease as diagnosed by Shionoya criteria Patients should have at least one ulcer (target ulcer): area between 0.5 to 10 cm2 (both inclusive) Ankle Brachial Pressure Index (ABPI) ≤ 0.6. If ABPI is ≥ 1.1 then Toe Brachial Index (TBI) will be performed and TBI should be ≤ 0.5 Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits Exclusion Criteria: Patients diagnosed with atherosclerotic peripheral arterial disease Patients eligible for surgical or percutaneous revascularization Patients with a history of participating in another stem cell trial or therapy within 3 months Patients who are unsuitable to participate the clinical trial as determined by investigators

Sites / Locations

  • Hospital Canselor Tunku Mukhriz

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Stempeucel®

Arm Description

Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml. The final concentration of components will be 1.5% HSA and 3% DMSO.

Outcomes

Primary Outcome Measures

Change in ischemic rest pain
Change in visual analog score (VAS) compared to screening
Change in size of the ulcer
Change in size of the ulcer compared to screening
Change in ankle brachial pressure index (ABPI)
Change in ankle brachial pressure index (ABPI) compared to screening
Change in total walking distance
Change in total walking distance on a treadmill compared to screening
Change in major amputation-free survival
Change in amputation-free survival compared to screening
Change in angiogenesis
Change in angiogenesis measured by digital subtraction angiogram (DSA) compared to screening

Secondary Outcome Measures

The type of AE(s), number of AE(s) and proportion of patients with AE(s)
AE(s) will be monitored and recorded as voluntarily disclosed by the patients and as observed by the investigator throughout the study
Incidence of abnormal laboratory test results (serum chemistry, haematology, liver function test)
The following lab tests will be conducted: serum chemistry, haematology, liver function test. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Incidence of abnormal urine test results
Urine test will be conducted. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Incidence of abnormal TNF-α
TNF-α test will be conducted. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Incidence of abnormal vital signs
The following assessments will be conducted: blood pressure, heart rate, respiratory rate and temperature. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Incidence of abnormal physical examination
The following examinations will be conducted: visual, heart, lungs, abdomen, nervous system, muscoskeletal system and etc. In case of abnormal conditions, they shall be recorded as an adverse event or excluded from study (screening).
Incidence of abnormal ECG parameters
The following assessments will be conducted: 12 lead ECG recordings with long Lead II, and two-dimensional echocardiography (2D ECHO; if needed). In case of abnormal conditions, they shall be recorded as an adverse event or excluded from study (screening).
Incidence of abnormal chest condition
Chest x-ray will be conducted. In case of abnormal conditions, they shall be recorded as an adverse event or excluded from study (screening).

Full Information

First Posted
March 30, 2023
Last Updated
May 2, 2023
Sponsor
Cell Biopeutics Resources Sdn Bhd
Collaborators
Stempeutics Research Pvt Ltd, National University of Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT05854615
Brief Title
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
Official Title
An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 2023 (Anticipated)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cell Biopeutics Resources Sdn Bhd
Collaborators
Stempeutics Research Pvt Ltd, National University of Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to Buerger's disease. The main questions it aims to answer are: Can intramuscular administration of Stempeucel® reduce symptoms of CLI due to Buerger's disease while improving the healing rate and functional outcomes? Does intramuscular administration of Stempeucel® causes any serious adverse events in CLI due to Buerger's disease patients? Study patients will be assessed by the PI before administering the Stempeucel® for any other organ with inflammation. The study patients will also be followed up to the duration of 1 year after study treatment administration for safety and efficacy assessment.
Detailed Description
Title: An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients with Critical Limb Ischemia (CLI) Due to Buerger's Disease Study Design: Single arm, practice-based, feasibility study Study Duration: Estimated duration for the main protocol (e.g. from starts of screening to last subject processed and end of the study) is approximately 18 months Study Center: Universiti Kebangsaan Malaysia Medical Centre (UKMMMC), Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Wilayah Persekutuan, Malaysia Objectives: To observe the efficacy and safety of Stempeucel® (adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells) in Malaysian patients with critical limb ischemia (CLI) due to Buerger's disease. Investigational Medicinal Product Description • Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO). Dosage • Dosing of Stempeucel® is based on body weight. The recommended dose is 2 million cells/kg body weight. Administration • 40 - 60 injections administered as 0.6 ml/kg (200 million bag) or 0.8 ml/kg (150 million bag) intramuscularly into different points on the muscle. Additional injections of 2 ml (200 million bag) or 3 ml (150 million bag) administered around the ulcer Number of Subjects 3 patients Data Analysis Data Management: Electronic case record form (eCRF) will be used for data entry. Oracle clinical (or other suitable alternatives with audit trail) will be used for data management. Statistical Method: The SPSS® package (IBM Inc., USA, version 22) will be used for statistical evaluation. All patients in the study with relevant efficacy and safety data will be considered for the analysis. Efficacy analysis will be done using GEE (Generalized Estimating Equations) method or paired t test as appropriate. Adverse events monitored using information voluntarily disclosed by the patients and as observed by the PI will be summarized descriptively by total number of AE(s). AEs will be categorized as: all AEs, all treatment-emergent AEs, all severe AEs, treatment-related AEs and severe treatment-related AEs. These events will be reported as appropriate and summarized.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Limb Ischemia, Buerger's Disease
Keywords
critical limb ischemia, Buerger's disease, bone marrow derived mesenchymal stem cell

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Stempeucel®
Arm Type
Experimental
Arm Description
Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml. The final concentration of components will be 1.5% HSA and 3% DMSO.
Intervention Type
Biological
Intervention Name(s)
Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
Other Intervention Name(s)
Stempeucel®
Intervention Description
• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
Primary Outcome Measure Information:
Title
Change in ischemic rest pain
Description
Change in visual analog score (VAS) compared to screening
Time Frame
Screening (Day -14 to -1), Day 30, 90, 180 and 360
Title
Change in size of the ulcer
Description
Change in size of the ulcer compared to screening
Time Frame
Screening (Day -14 to -1), Day 30, 90, 180 and 360
Title
Change in ankle brachial pressure index (ABPI)
Description
Change in ankle brachial pressure index (ABPI) compared to screening
Time Frame
Screening (Day -14 to -1), Day 30, 90, 180 and 360
Title
Change in total walking distance
Description
Change in total walking distance on a treadmill compared to screening
Time Frame
Screening (Day -14 to -1), Day 30, 90, 180 and 360
Title
Change in major amputation-free survival
Description
Change in amputation-free survival compared to screening
Time Frame
Screening (Day -14 to -1), Day 30, 90, 180 and 360
Title
Change in angiogenesis
Description
Change in angiogenesis measured by digital subtraction angiogram (DSA) compared to screening
Time Frame
Screening (Day -14 to -1), Day 180
Secondary Outcome Measure Information:
Title
The type of AE(s), number of AE(s) and proportion of patients with AE(s)
Description
AE(s) will be monitored and recorded as voluntarily disclosed by the patients and as observed by the investigator throughout the study
Time Frame
Screening (Day -14 to -1)
Title
Incidence of abnormal laboratory test results (serum chemistry, haematology, liver function test)
Description
The following lab tests will be conducted: serum chemistry, haematology, liver function test. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Day 7, 30, 90, 180 and 360
Title
Incidence of abnormal urine test results
Description
Urine test will be conducted. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Day 180
Title
Incidence of abnormal TNF-α
Description
TNF-α test will be conducted. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Day 7 and 30
Title
Incidence of abnormal vital signs
Description
The following assessments will be conducted: blood pressure, heart rate, respiratory rate and temperature. In case of abnormal results, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Baseline, Day 7, 30, 90, 180 and 360
Title
Incidence of abnormal physical examination
Description
The following examinations will be conducted: visual, heart, lungs, abdomen, nervous system, muscoskeletal system and etc. In case of abnormal conditions, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Baseline, Day 7, 30, 90, 180 and 360
Title
Incidence of abnormal ECG parameters
Description
The following assessments will be conducted: 12 lead ECG recordings with long Lead II, and two-dimensional echocardiography (2D ECHO; if needed). In case of abnormal conditions, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Baseline, Day 7, 30, 90, 180 and 360
Title
Incidence of abnormal chest condition
Description
Chest x-ray will be conducted. In case of abnormal conditions, they shall be recorded as an adverse event or excluded from study (screening).
Time Frame
Screening (Day -14 to -1), Day 180

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 years. Buerger's disease as diagnosed by Shionoya criteria Patients should have at least one ulcer (target ulcer): area between 0.5 to 10 cm2 (both inclusive) Ankle Brachial Pressure Index (ABPI) ≤ 0.6. If ABPI is ≥ 1.1 then Toe Brachial Index (TBI) will be performed and TBI should be ≤ 0.5 Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits Exclusion Criteria: Patients diagnosed with atherosclerotic peripheral arterial disease Patients eligible for surgical or percutaneous revascularization Patients with a history of participating in another stem cell trial or therapy within 3 months Patients who are unsuitable to participate the clinical trial as determined by investigators
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jezamine Lim, PhD
Phone
+60176073103
Email
info@cellbiopeutics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hanafiah Harunarashid, MS
Organizational Affiliation
National University of Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Canselor Tunku Mukhriz
City
Kuala Lumpur
ZIP/Postal Code
56000
Country
Malaysia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Farhana Raduan, MS
Phone
+603-9145
Ext
8299
Email
farhana@ppukm.ukm.edu.my
First Name & Middle Initial & Last Name & Degree
Hanafiah Harunarashid, MS
First Name & Middle Initial & Last Name & Degree
Lenny Suryani Safri, MS
First Name & Middle Initial & Last Name & Degree
Mohamad Azim Md Idris, MS

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
18048472
Citation
Haugen S, Casserly IP, Regensteiner JG, Hiatt WR. Risk assessment in the patient with established peripheral arterial disease. Vasc Med. 2007 Nov;12(4):343-50. doi: 10.1177/1358863X07083278.
Results Reference
background
PubMed Identifier
18376183
Citation
Sprengers RW, Lips DJ, Moll FL, Verhaar MC. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg. 2008 Mar;247(3):411-20. doi: 10.1097/SLA.0b013e318153fdcb.
Results Reference
background
PubMed Identifier
10777241
Citation
Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999 Jun;12(2):142-7.
Results Reference
background
PubMed Identifier
16631394
Citation
Gottsater A. Managing risk factors for atherosclerosis in critical limb ischaemia. Eur J Vasc Endovasc Surg. 2006 Nov;32(5):478-83. doi: 10.1016/j.ejvs.2006.03.007. Epub 2006 Apr 24.
Results Reference
background
PubMed Identifier
23197862
Citation
Schiavetta A, Maione C, Botti C, Marino G, Lillo S, Garrone A, Lanza L, Pagliari S, Silvestroni A, Signoriello G, Sica V, Cobellis G. A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study. Stem Cells Transl Med. 2012 Jul;1(7):572-8. doi: 10.5966/sctm.2012-0021. Epub 2012 Jul 6.
Results Reference
background
PubMed Identifier
19740466
Citation
Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis. 2010 Mar;209(1):10-7. doi: 10.1016/j.atherosclerosis.2009.08.033. Epub 2009 Aug 21.
Results Reference
background
PubMed Identifier
19897335
Citation
Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, Nehler MR, Powell RJ, Sidawy AN. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009 Dec;50(6):1462-73.e1-3. doi: 10.1016/j.jvs.2009.09.044. Epub 2009 Nov 7.
Results Reference
background
PubMed Identifier
16828434
Citation
Marston WA, Davies SW, Armstrong B, Farber MA, Mendes RC, Fulton JJ, Keagy BA. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg. 2006 Jul;44(1):108-114. doi: 10.1016/j.jvs.2006.03.026.
Results Reference
background
PubMed Identifier
24414120
Citation
Gupta NK, Armstrong EJ, Parikh SA. The current state of stem cell therapy for peripheral artery disease. Curr Cardiol Rep. 2014 Feb;16(2):447. doi: 10.1007/s11886-013-0447-2.
Results Reference
background
PubMed Identifier
18476781
Citation
Tachi Y, Fukui D, Wada Y, Koshikawa M, Shimodaira S, Ikeda U, Amano J. Changes in angiogenesis-related factors in serum following autologous bone marrow cell implantation for severe limb ischemia. Expert Opin Biol Ther. 2008 Jun;8(6):705-12. doi: 10.1517/14712598.8.6.705.
Results Reference
background
PubMed Identifier
19500466
Citation
Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009;18(3):371-80. doi: 10.3727/096368909788534942. Epub 2009 Apr 2.
Results Reference
background
PubMed Identifier
27293053
Citation
Molavi B, Zafarghandi MR, Aminizadeh E, Hosseini SE, Mirzayi H, Arab L, Baharvand H, Aghdami N. Safety and Efficacy of Repeated Bone Marrow Mononuclear Cell Therapy in Patients with Critical Limb Ischemia in a Pilot Randomized Controlled Trial. Arch Iran Med. 2016 Jun;19(6):388-96.
Results Reference
background
PubMed Identifier
27021379
Citation
Liang TW, Jester A, Motaganahalli RL, Wilson MG, G'Sell P, Akingba GA, Fajardo A, Murphy MP. Autologous bone marrow mononuclear cell therapy for critical limb ischemia is effective and durable. J Vasc Surg. 2016 Jun;63(6):1541-5. doi: 10.1016/j.jvs.2016.01.022. Epub 2016 Mar 23.
Results Reference
background
PubMed Identifier
17140820
Citation
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group; Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75. doi: 10.1016/j.ejvs.2006.09.024. Epub 2006 Nov 29. No abstract available.
Results Reference
background
PubMed Identifier
20174766
Citation
Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost. 2010 Apr;103(4):696-709. doi: 10.1160/TH09-10-0688. Epub 2010 Feb 19.
Results Reference
background
PubMed Identifier
9020076
Citation
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997 Feb 14;275(5302):964-7. doi: 10.1126/science.275.5302.964.
Results Reference
background
PubMed Identifier
9657732
Citation
Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998 Jul 15;92(2):362-7.
Results Reference
background
PubMed Identifier
12241713
Citation
Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 Aug 10;360(9331):427-35. doi: 10.1016/S0140-6736(02)09670-8.
Results Reference
background
PubMed Identifier
16682507
Citation
Lu Y, Wang Z, Zhu M. Human bone marrow mesenchymal stem cells transfected with human insulin genes can secrete insulin stably. Ann Clin Lab Sci. 2006 Spring;36(2):127-36.
Results Reference
background
PubMed Identifier
15153614
Citation
Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22(3):377-84. doi: 10.1634/stemcells.22-3-377.
Results Reference
background
PubMed Identifier
12589164
Citation
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15;75(3):389-97. doi: 10.1097/01.TP.0000045055.63901.A9.
Results Reference
background
PubMed Identifier
11986244
Citation
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002 May 15;99(10):3838-43. doi: 10.1182/blood.v99.10.3838.
Results Reference
background
PubMed Identifier
10102814
Citation
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7. doi: 10.1126/science.284.5411.143.
Results Reference
background
PubMed Identifier
10704367
Citation
Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci. 2000 Apr;113 ( Pt 7):1161-6. doi: 10.1242/jcs.113.7.1161.
Results Reference
background
PubMed Identifier
11458512
Citation
Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci. 2001 Jun;938:231-3; discussion 233-5. doi: 10.1111/j.1749-6632.2001.tb03593.x.
Results Reference
background
PubMed Identifier
11166464
Citation
Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol. 2001 Feb;29(2):244-55. doi: 10.1016/s0301-472x(00)00635-4.
Results Reference
background
PubMed Identifier
15860974
Citation
Bhatia R, Hare JM. Mesenchymal stem cells: future source for reparative medicine. Congest Heart Fail. 2005 Mar-Apr;11(2):87-91; quiz 92-3. doi: 10.1111/j.1527-5299.2005.03618.x.
Results Reference
background
PubMed Identifier
11171801
Citation
Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation. 2001 Feb 13;103(6):897-903. doi: 10.1161/01.cir.103.6.897.
Results Reference
background
PubMed Identifier
11524400
Citation
Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A, Shintani S, Murohara T, Imaizumi T, Iwasaka T. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001 Aug 28;104(9):1046-52. doi: 10.1161/hc3501.093817.
Results Reference
background
PubMed Identifier
12370229
Citation
Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, Kojima H, Iwasaka T. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation. 2002 Oct 8;106(15):2019-25. doi: 10.1161/01.cir.0000031332.45480.79.
Results Reference
background
PubMed Identifier
10725398
Citation
Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7. doi: 10.1073/pnas.97.7.3422.
Results Reference
background
PubMed Identifier
17615264
Citation
Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007 Oct;25(10):2648-59. doi: 10.1634/stemcells.2007-0226. Epub 2007 Jul 5.
Results Reference
background
PubMed Identifier
15145218
Citation
Mahmud N, Pang W, Cobbs C, Alur P, Borneman J, Dodds R, Archambault M, Devine S, Turian J, Bartholomew A, Vanguri P, Mackay A, Young R, Hoffman R. Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model. Exp Hematol. 2004 May;32(5):494-501. doi: 10.1016/j.exphem.2004.02.010.
Results Reference
background
PubMed Identifier
10627466
Citation
Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF, Sauvage LR, Hammond WP, Wu MH. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood. 2000 Jan 15;95(2):581-5.
Results Reference
background
PubMed Identifier
11266284
Citation
Ikenaga S, Hamano K, Nishida M, Kobayashi T, Li TS, Kobayashi S, Matsuzaki M, Zempo N, Esato K. Autologous bone marrow implantation induced angiogenesis and improved deteriorated exercise capacity in a rat ischemic hindlimb model. J Surg Res. 2001 Apr;96(2):277-83. doi: 10.1006/jsre.2000.6080.
Results Reference
background
PubMed Identifier
12388231
Citation
Hirata K, Li TS, Nishida M, Ito H, Matsuzaki M, Kasaoka S, Hamano K. Autologous bone marrow cell implantation as therapeutic angiogenesis for ischemic hindlimb in diabetic rat model. Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H66-70. doi: 10.1152/ajpheart.00547.2002. Epub 2002 Sep 19.
Results Reference
background
PubMed Identifier
23758736
Citation
Gupta PK, Chullikana A, Parakh R, Desai S, Das A, Gottipamula S, Krishnamurthy S, Anthony N, Pherwani A, Majumdar AS. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013 Jun 10;11:143. doi: 10.1186/1479-5876-11-143.
Results Reference
background
PubMed Identifier
28297569
Citation
Gupta PK, Krishna M, Chullikana A, Desai S, Murugesan R, Dutta S, Sarkar U, Raju R, Dhar A, Parakh R, Jeyaseelan L, Viswanathan P, Vellotare PK, Seetharam RN, Thej C, Rengasamy M, Balasubramanian S, Majumdar AS. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy. Stem Cells Transl Med. 2017 Mar;6(3):689-699. doi: 10.5966/sctm.2016-0237. Epub 2016 Oct 5.
Results Reference
background
PubMed Identifier
24438903
Citation
Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, Saint-Lebese B, Peyrafitte JA, Fleury S, Gadelorge M, Taurand M, Dupuis-Coronas S, Leobon B, Casteilla L. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy. 2014 Feb;16(2):245-57. doi: 10.1016/j.jcyt.2013.11.011.
Results Reference
background
PubMed Identifier
18450207
Citation
Wester T, Jorgensen JJ, Stranden E, Sandbaek G, Tjonnfjord G, Bay D, Kolleros D, Kroese AJ, Brinchmann JE. Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. A pilot study. Scand J Surg. 2008;97(1):56-62. doi: 10.1177/145749690809700108.
Results Reference
background
Citation
Debin L, Youzhao J, Ziwen L, et al. Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. Journal of Medical Colleges of PLA. 2008; 23(2): 106-155. doi: 10.1016/S1000-1948(08)60031-3
Results Reference
background
PubMed Identifier
21205941
Citation
Idei N, Soga J, Hata T, Fujii Y, Fujimura N, Mikami S, Maruhashi T, Nishioka K, Hidaka T, Kihara Y, Chowdhury M, Noma K, Taguchi A, Chayama K, Sueda T, Higashi Y. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv. 2011 Feb 1;4(1):15-25. doi: 10.1161/CIRCINTERVENTIONS.110.955724. Epub 2011 Jan 4.
Results Reference
background
PubMed Identifier
16631737
Citation
Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006 Jul 15;312(12):2169-79. doi: 10.1016/j.yexcr.2006.03.019. Epub 2006 Apr 24.
Results Reference
background
Citation
ICH Topic E 2 A:Clinical Safety Data Management: Definitions and Standards for Expedited Reporting-(CPMP/ICH/377/95)
Results Reference
background
Citation
Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India. Draft Guidelines on Audio-Visual Recording of Informed Consent Process in Clinical Trial. 2014. [cited 2016 Jul 29]. Available from: http://www.cdsco.nic.in/writereaddata/Guidance_for_AV%20Recording_09.January.14.pdf.
Results Reference
background
Citation
ClinicalTrials.gov. Identifier NCT01257776, Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01079403
Results Reference
background

Learn more about this trial

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

We'll reach out to this number within 24 hrs